Literature DB >> 3606544

Comparison of cardiac and hemodynamic effects of platelet-activating factor-acether and leukotriene D4 in anesthetized dogs.

V B Fiedler, M Mardin, T S Abram.   

Abstract

In anesthetized dogs, platelet-activating factor-acether (PAF; 0.2-1.6 micrograms/kg) and leukotriene (LT) D4 (0.5, 1, and 3 micrograms/kg) were injected into the left circumflex (LCX) coronary artery. Cardiac and systemic hemodynamics, and the ECG were continuously recorded. PAF reduced cardiac performance and affected hemodynamics in a dose-dependent manner: At 7 +/- 3s, LCX flow initially increased by 40%-172% followed by a reduction of 43%-100%, and coronary diameter (measured with ultrasonic techniques) decreased by 4%-10%. Total and late coronary resistance increased. Left ventricular (LV) systolic pressure fell by 22%-48% and LV filling pressure decreased by 5 mm Hg after 0.8 microgram/kg PAF. The LVdP/dtmax diminished by 38%-47%. Peak blood pressure reduction (35%) occurred 60 s after PAF application and lasted for 1.4 min. Heart rate decreased by 10%-17% at peak PAF actions. LTD4 reduced LCX flow by 38%-87%, and coronary diameter by 5%-12%, returning to control value within 3.4 min. Blood pressure, LV pressure, and LVdP/dtmax decreased while heart rate and LV filling pressure increased. ST segments and R-wave voltage of the ECG in lead II elevated after either compound although the effects were more pronounced after LTD4. Indomethacin (5 mg/kg i.v.) pretreatment did not affect LTD4 actions on cardiohemodynamics, but the putative leukotriene antagonist FPL 55712 (1 mg/kg i.v.) blocked LTD4 actions on the heart and circulation. PAF influences on LCX flow were modified by indomethacin: initial flow rose by 250%, and coronary diameter fell by 12%, followed by sustained flow and diameter reduction during the second phase on PAF action. FPL 55712 did not affect the early flow increase after PAF but attenuated the later flow reduction, which was blocked by indomethacin. Thus, PAF and LTD4 may have effects on canine conduit arteries besides their effects on the coronary resistance vessels. The circulatory derangement after PAF may be aggravated by additional eicosanoid release. PAF and LTD4 may be involved in coronary blood flow variations and negative inotropy accompanying anaphylactic disease state.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606544     DOI: 10.1007/bf01907067

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  41 in total

1.  The production of the arachidonate metabolite HETE in vascular tissue.

Authors:  J E Greenwald; J R Bianchine; L K Wong
Journal:  Nature       Date:  1979-10-18       Impact factor: 49.962

2.  The role of platelet-activating factor in platelet aggregation.

Authors:  M Chignard; J P Le Couedic; M Tence; B B Vargaftig; J Benveniste
Journal:  Nature       Date:  1979-06-28       Impact factor: 49.962

Review 3.  Role of endothelium in responses of vascular smooth muscle.

Authors:  R F Furchgott
Journal:  Circ Res       Date:  1983-11       Impact factor: 17.367

4.  Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs.

Authors:  P Bessin; J Bonnet; D Apffel; C Soulard; L Desgroux; I Pelas; J Benveniste
Journal:  Eur J Pharmacol       Date:  1983-01-21       Impact factor: 4.432

5.  Novel epoxides formed during the liver cytochrome P-450 oxidation of arachidonic acid.

Authors:  N Chacos; J R Falck; C Wixtrom; J Capdevila
Journal:  Biochem Biophys Res Commun       Date:  1982-02-11       Impact factor: 3.575

6.  Negative inotropic effect of leukotrienes: leukotrienes C4 and D4 inhibit calcium-dependent contractile responses in potassium-depolarized guinea-pig myocardium.

Authors:  Y Hattori; R Levi
Journal:  J Pharmacol Exp Ther       Date:  1984-09       Impact factor: 4.030

7.  Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes.

Authors:  J M Mencia-Huerta; J Benveniste
Journal:  Eur J Immunol       Date:  1979-05       Impact factor: 5.532

8.  Leukotrienes C4, D4 and E4: effects on human and guinea-pig cardiac preparations in vitro.

Authors:  J A Burke; R Levi; Z G Guo; E J Corey
Journal:  J Pharmacol Exp Ther       Date:  1982-04       Impact factor: 4.030

9.  Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources.

Authors:  R A Lewis; K F Austen; J M Drazen; D A Clark; A Marfat; E J Corey
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

10.  Leukotriene D4: a potent coronary artery vasoconstrictor associated with impaired ventricular contraction.

Authors:  F Michelassi; L Landa; R D Hill; E Lowenstein; W D Watkins; A J Petkau; W M Zapol
Journal:  Science       Date:  1982-08-27       Impact factor: 47.728

View more
  4 in total

1.  Characterization of the coronary vascular responses to platelet-activating factor in the isolated perfused heart.

Authors:  W M Hu; P C Choy; R Y Man
Journal:  Lipids       Date:  1991-09       Impact factor: 1.880

2.  Mechanisms of the coronary vascular effects of platelet-activating factor in the rat perfused heart.

Authors:  W Hu; A A Kinnaird; R Y Man
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

3.  Involvement of nitric oxide and eicosanoids in platelet-activating factor-induced haemodynamic and haematological effects in dogs.

Authors:  K Noguchi; T Matsuzaki; N Shiroma; Y Ojiri; M Sakanashi
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

4.  Interaction of vasoactive substances released by platelet-activating factor in the rat perfused heart.

Authors:  W M Hu; R Y Man
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.